selected publications
-
academic article
- TYK2 regulates tau levels, phosphorylation and aggregation in a tauopathy mouse model.. Nature Neuroscience. 27:2417-2429. 2024
- APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease.. Molecular therapy : the journal of the American Society of Gene Therapy. 32:1373-1386. 2024
- Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease.. Annals of Neurology. 95:625-634. 2024
- Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model.. Annals of neurology. 89:952-966. 2021
- Alzheimer disease. Nature Reviews Disease Primers. 2021
- Alternatives to amyloid for Alzheimer's disease therapies-a symposium report.. Annals of the New York Academy of Sciences. 1475:3-14. 2020
- Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.. The Journal of clinical investigation. 128:2144-2155. 2018
- Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.. Neurology. 89:2381-2391. 2017
- Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.. The Journal of neuroscience : the official journal of the Society for Neuroscience. 34:7281-92. 2014
- Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.. Brain : a journal of neurology. 135:2155-68. 2012
- Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease.. Nature. 451:720-4. 2008
- National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards.. Stroke. 37:2220-41. 2006